On-chip anticancer drug screening – Recent progress in microfluidic platforms to address challenges in chemotherapy.

On-chip anticancer drug screening – Recent progress in microfluidic platforms to address challenges in chemotherapy.

Publication date: Jul 15, 2019

There is an increasing need for advanced and inexpensive preclinical models to accelerate the development of anticancer drugs. While costly animal models fail to predict human clinical outcomes, in vitro models such as microfluidic chips (‘tumor-on-chip’) are showing tremendous promise at predicting and providing meaningful preclinical drug screening outcomes. Research on ‘tumor-on-chips’ has grown enormously worldwide and is being widely accepted by pharmaceutical companies as a drug development tool. In light of this shift in philosophy, it is important to review the recent literature on microfluidic devices to determine how rapidly the technology has progressed as a promising model for drug screening and aiding cancer therapy. We review the past five years of successful developments and capabilities in microdevice technology (cancer models) for use in anticancer drug screening. Microfluidic devices that are being designed to address current challenges in chemotherapy, such as drug resistance, combinatorial drug therapy, personalized medicine, and cancer metastasis are also reviewed in detail. We provide a perspective on how personalized ‘tumor-on-chip’, as well as high-throughput microfluidic platforms based on patient-specific tumor cells, can potentially replace the more expensive and ‘non-human’ animal models in preclinical anticancer drug development.

Dhiman, N., Kingshott, P., Sumer, H., Sharma, C.S., and Rath, S.N. On-chip anticancer drug screening – Recent progress in microfluidic platforms to address challenges in chemotherapy. 05000. 2019 Biosens Bioelectron (137):

Concepts Keywords
Cancer Perspective personalized tumor
Chemotherapy Medicine metastasis
Chips Patient specific tumor
Combinatorial Drug therapy
Drug Development Chemotherapy
Drug Resistance Nanotechnology
Drug Therapy Articles
Metastasis Materials science
Microfluidic Microfluidics
Personalized Medicine Medicine
Pharmaceutical Companies Biotechnology
Philosophy Cancer treatments
Throughput Antineoplastic drugs
Tumor Chemotherapy
Lab-on-a-chip
Organ-on-a-chip
Microfluidics
Drug screening
Drug development
Chemotherapy

Semantics

Type Source Name
disease MESH metastasis
gene UNIPROT EHD1
disease DOID cancer
disease MESH cancer
gene UNIPROT TNFSF14
disease MESH development
gene UNIPROT STUB1

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *